Amlodipine/rosuvastatin/telmisartan - Yuhan

Drug Profile

Amlodipine/rosuvastatin/telmisartan - Yuhan

Alternative Names: Amlodipine/telmisartan/rosuvastatin; Rosuvastatin/amlodipine/telmisartan; Rosuvastatin/telmisartan/amlodipine; Telmisartan/amlodipine/rosuvastatin; Telmisartan/rosuvastatin/amlodipine; YH 22189; YHP 1604

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Yuhan
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipidaemia; Hypertension

Most Recent Events

  • 12 Apr 2017 Yuhan plans a phase I trial in Healthy volunteers in South Korea (PO) (NCT03116516)
  • 31 Oct 2016 Yuhan plans a phase III trial for Hypertension and Hyperlipidaemia in South Korea (PO)
  • 28 Oct 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top